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Pitfalls in the diagnosis and 
management of aortic stenosis
It is important to remember that AS is not a disease confi ned 
to the elderly population. Congenital AS presents in the young 
and rheumatic AS is still encountered in developing countries. 
Rheumatic AS frequently coexists with aortic regurgitation and 
mitral valve disease and it is well recognised that clinical severity 
of aortic stenosis may be underestimated in the face of signifi -
cant mitral stenosis. 
This article will highlight some of the common pitfalls and address 
some of the controversies in the diagnosis and management of 
primary calcifi c AS.
PITFALLS IN THE CLINICAL DIAGNOSIS OF AS         
The diagnosis of AS begins with a detailed history and physical 
examination.  
In primary calcifi c AS, there is usually a long latent asympto-
matic period before symptoms develop usually in the sixth decade 
of life.  History taking must determine whether patients are indeed 
symptomatic (the classic symptoms being angina, dyspnoea and 
syncope) or not, keeping in mind that many patients will 
often reduce their physical activity to compensate for “minor 
symptoms”. Patients may also present with non-specifi c symptoms 
such as dizziness, fatigue or unsteadiness on exercise which 
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INTRODUCTION                                                              
AS has become the most frequent valvular heart disease and the 
most frequent cardiovascular disease after hypertension and 
coronary artery disease in the Western world.  The prevalence of 
AS in the population older than 65 years is between 2-7% and 
is expected to rise with an aging population.(1)    
The most common form is primary calcifi c AS, a disease charac-
terised by progressive leafl et calcifi cation and fi brosis that results 
in left ventricular (LV) outfl ow obstruction with symptom onset 
in the sixth decade.  Once thought to be purely an age-related 
or degenerative disease, it is now well accepted that this condition 
is an infl ammatory disease similar to atherosclerosis.  When this 
disease process involves bicuspid aortic valves, patients usually 
present one to two decades earlier.  When the aortic valve is 
diseased (possibly calcifi ed), but non-obstructive, the term aortic 
sclerosis is applied.  We consider this unwise and prefer to use the 
term aortic valve disease with minimal or no gradient.  Aortic 
sclerosis is a precursor of calcifi c AS with an average time of 
progression to severe AS of 8 years.(2)  The rate of progression in 
any individual is unpredictable and labelling patients as “aortic 
sclerosis” creates a false sense of complacency and comfort. 
All patients with clinically detectable aortic valve disease require 
careful serial monitoring to detect disease progression.
In many instances the diagnosis and management of aortic 
stenosis (AS) is straightforward. In others, however, the 
diagnosis and management of AS can be extraordinary 
diffi cult.  Clinicians need to be aware of the pitfalls in diagnosis 
and management. Diagnosis and assessment of disease 
severity begins with a detailed history and physical 
examination.  Echocardiography in experienced hands is the 
standard investigation of choice to confi rm the diagnosis and 
to assess its severity.  While the treatment of symptomatic 
severe AS is surgery, asymptomatic patients with severe 
aortic disease and concomitant disease, like hypertension, 




















have the same signifi cance as episodes of syncope or dyspnoea.  It 
must be remembered that dyspnoea on exertion, orthopnoea 
and PND are usually late symptoms of AS.
The classical teaching is that severe AS causes a small, slow-
rising pulse, a loud long ejection systolic murmur, a soft or absent 
second heart sound and systemic hypotension with a reduced 
pulse pressure. However, not all patients will have these signs. 
A combination of a right clavicular murmur and the following signs: 
a reduced carotid upstroke; reduced carotid volume; soft second 
heart sound; and a maximal murmur intensity at the right sternal 
edge, strongly predicts moderate or severe AS.(3,4)
The classic delayed rise of the pulse can be absent even with severe 
disease particularly in the elderly population with an inelastic 
arterial bed.  Although hypotension and a low pulse pressure may 
be signs of AS, a normal blood pressure or even severe hyper-
tension does not exclude AS. Between 22-40% of patients 
requiring aortic valve replacement have a systolic blood pressure of 
> 130mmHg.(5,6)  Not all murmurs of AS will radiate to the neck. 
The murmur may best be heard at the apex (Gallavardin’s 
phenomenon) and may be confused with mitral regurgitation. 
Listening carefully for post-ectopic accentuation of the murmur 
which occurs with AS, but not with mitral regurgitation, can be 
a helpful distinguishing feature.  It is important to note that when 
LV dysfunction occurs, the murmur intensity may decrease or 
disappear completely despite severe valve obstruction or so-called 
occult AS.  The clinician needs to look for other clues for the 
presence of AS including observing calcifi cation of the aortic 
valve which is found in nearly all patients > 50 years with severe 
AS and LV hypertrophy on ECG which is seen in 85% of patients 
with signifi cant AS.(7)
 
In the differential diagnosis of AS always consider hypertrophic 
obstructive cardiomyopathy and congenital sub/supravalvar aortic 
stenosis in younger patients. The murmur of hypertrophic 
cardiomyopathy softens on squatting and increases in intensity 
during the valsalva manoeuvre and when standing, which 
reduces transvalvular fl ow.  Consider sub/supravalvar AS in a 
patient with suspected congenital valvar AS without an ejection 
systolic click.
In summary, the clinical signs of AS may be unreliable and there 
should be a low threshold for requesting a diagnostic echocardio-
gram in a patient where the diagnosis is suspected.  
PITFALLS IN THE ASSESSMENT OF DISEASE             
SEVERITY BY ECHOCARDIOGRAPHY
All patients with a clinical diagnosis of AS should have an 
echocardiogram to confi rm the diagnosis and to assess disease 
severity.
Echocardiography provides anatomic imaging of the possible 
underlying aetiology, level of obstruction, degree of valve calcifi ca-
tion, aortic root anatomy and the left ventricle’s response to the 
disease. The maximal transvalvular aortic jet velocity, mean 
transvalvular gradient and aortic valve area using the continuity 
equation can be measured and calculated.
AS can be graded as mild, moderate or severe.(8)
Accurate echocardiographic quantifi cation of AS severity is a 
technically demanding procedure. The echocardiographer must 
ensure that the transducer and continuous wave doppler profi le 
is obtained parallel with the aortic jet. Any deviation from a 
parallel intercept angle will result in underestimation of jet velocity. 
Several acoustic windows with optimal patient positioning and 
the use of the non-imaging continuous wave doppler transducer 
(stand-alone probe) are often needed.  Although aortic jet velocity 
is the most reproducible measurement one has to be careful 
about assessing the severity of AS using velocities or gradients 
alone. Gradient is infl uenced by stroke volume, systolic ejection 
time, heart rate, preload, afterload and contractility. As a result 
gradient can often vary from one time to another. Aortic valve 
area calculation factors in some of these variables and is less 
infl uenced by variable haemodynamic states, but is less repro-
ducible and is more prone to errors in measurement.(9)
Mild AS 2.6-3.0 m.s-1 AVA > 1.5cm2  Mean gradient < 25mmHg
Moderate AS  3.0-4.0 m.s-1 AVA = 1.0-1.5cm2 Mean gradient = 25-40mmHg
Severe AS  > 4.0 m.s-1 AVA <= 1.0cm2 Mean gradient > 40mmHg
  AVA index 
  <0.6cm2/m2
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Aortic valve area determined by echocardiography is calculated 
using the continuity equation. 
LV outfl ow tract diameter is measured in midsystole just 
proximal to and parallel with the plane of the aortic valve from 
the inner edge of the septal echo to the leading edge of the base 
of the anterior mitral leafl et. Small errors in outfl ow tract 
diameter may lead to large errors in calculated cross-sectional 
area as the diameter is squared in the equation to calculate CSA. 
Multiple readings need to be taken.(9)
Co-existing moderate to severe aortic regurgitation may result 
in a falsely high transvalvar pressure gradient (due to a high 
transvalvar fl ow rate), but valve area calculations are still accurate 
because transvalvar stroke volume in the continuity equation 
still represents transvalvar stroke volume.  Conversely, LV systolic 
dysfunction with severe AS can result in falsely low transvalvar 
pressure gradient because of a low transvalvar fl ow rate.  Although 
calculation of valve area is less fl ow-dependent than pressure 
gradients, valve area can fall in parallel with fl ow rate and thus 
the valve area can be reduced even when the stenosis is not 
severe in patients with LV systolic dysfunction.(9) 
 
There is a wide variation in the correlation of symptoms with 
the severity of AS defi ned by velocity, gradient or valve area. 
Generally, symptoms can be attributed to AS if the aortic valve 
area is < 1.0 cm2 or if the transvalvar velocity > 4m.s-1.(10) There 
is signifi cant overlap of all measures of haemodynamic severity 
between symptomatic and asymptomatic patients and it is not 
unusual to see asymptomatic patients with a transvalvar velocity 
> 4m.s-1. Furthermore, the rate of haemodynamic progression 
is highly variable between patients. On average, transvalvar 
velocities increase by 0.3m.sec/year and valve area decreases by 
0.1cm2/year.(9)
PITFALLS IN  THE ASSESSMENT OF DISEASE            
SEVERITY BY CARDIAC CATHETERISATION
Cardiac catheterisation is reserved for patients where echo-
cardiographic data is non-diagnostic or when clinical and 
echocardiographic data are discrepant.  Heavily calcifi ed aortic 
valves should not be crossed with a catheter because of the risks 
of peripheral embolisation.  A careful left ventricle to aorta pull-
back is particularly useful to exclude subvalvar or supravalvar 
AS. When the aortic valve cannot be crossed by a catheter and 
the diagnosis is still in doubt, a trans-septal puncture must be 
performed with simultaneous measurement of LV and aortic 
pressures. When performing a LV to aorta pullback it is 
important to measure transvalvar pressures in the ascending 
aorta just distal to the aortic valve using an end-hole catheter as 
peripheral amplifi cation of aortic pressures may lead to false 
reduction in the peak and mean gradients. Calculation of aortic 
valve area using the Gorlin equation is fl ow-dependent. There-
fore, patients with LV dysfunction and a low cardiac output 
may have a low calculated valve area even in the presence of 
mild AS (see AS with reduced EF below).(11)   
PITFALLS IN THE MANAGEMENT OF AS                      
Symptomatic AS
There is no debate with regards to the management of sympto-
matic, severe AS. Patients should have an aortic valve replace-
ment as soon as the classic symptoms of angina, syncope or 
dyspnoea develop in the absence of surgical contra-indications. 
This recommendation is supported by the landmark survival data 
of Ross and Braunwald who showed a 75% 3 year mortality 
in symptomatic AS patients without valve surgery compared to 
near-normal age-corrected survival for patients who underwent 
valve surgery.(12) They clearly showed that 50% of patients with 
AS who present with angina survive 5 years; 50% of patients 
with syncope survive 3 years; and only 50% of patients with heart 
failure survive 2 years. Symptomatic patients with moderate AS 
that have no other explanations for symptoms should also be 
considered for valve surgery.
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CSA (LVOT)  x   VTI (LVOT) / VTI (AS) 
CSA (LVOT)  =  ∏ (D/2)
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The asymptomatic patient with moderate or severe AS has 
an excellent prognosis and should be followed up at 6 monthly 
intervals.  They should be advised to report to their doctor or 
cardiologist as soon as symptoms develop because symptomatic 
patients, even for a period of a few months, have a poorer prog-
nosis. The prognosis of asymptomatic patients is not completely 
benign as there is small incidence of sudden cardiac death 
(0.4%/year) with severe valve obstruction.(13) This risk is too low 
to recommend routine aortic valve replacement in every severe, 
asymptomatic patient as the operative risks of surgery (3-4%) and 
the risks of living with a prosthetic valve outweigh the small 
benefi t of prevention of sudden cardiac death. The onset of 
symptoms can be diffi cult to assess as some patients may 
subconsciously adapt and reduce their daily activities. Approxi-
mately 1/3 of asymptomatic patients will become symptomatic 
within 2 years.(14)  Asymptomatic patients with moderate or severe 
AS undergoing coronary artery bypass grafting, surgery of the 
ascending aorta or mitral valve surgery should undergo concomitant 
aortic valve replacement.        
The use of exercise stress testing to further risk stratify asympto-
matic patients with severe AS is controversial. The ACC/AHA 
guidelines recommend exercise stress testing when patients’ 
symptoms are unclear but it is a Class IIb recommendation.(8) 
It does not form part of our routine practice for a number of 
reasons. There is currently no good evidence that this strategy 
decreases mortality in patients with severe asymptomatic AS 
as compared to watchful waiting. Although, exercise testing may 
be useful to predict symptom onset in patients with asympto-
matic severe AS, a study by Das et al. showed that symptoms with 
exercise stress testing had a positive accuracy of only 65% and 
a negative accuracy of 73% to predict the onset of symptoms in 
the following 12 months.(15) Exertional dizziness rather than 
chest tightness or dyspnoea on exercise was a more reliable 
marker to predict symptoms in the following 12 months. The 
demonstration of breathlessness or chest tightness on a treadmill 
in an elderly patient with a limited exercise capacity is diffi cult 
to interpret as physical fi tness clearly infl uences symptom 
interpretation and underlying coronary artery disease may 
mimick symptoms of AS. It has been stated that exercise stress 
testing is more useful in active patients <= 70 yrs of age, but 
these are a group of patients where symptom onset is generally 
easier to defi ne.  Furthermore, the utility of ST-segment changes 
or an abnormal blood pressure response with exercise does not 
give additional prognostic information over symptoms alone. 
The ACC/AHA guidelines state that severe LV hypertrophy 
(>= 15mm) not due to hypertension, or ventricular arrhythmias 
for which no other cause can be identifi ed, can be used to 
further risk stratify asymptomatic patients and receive Class IIb 
recommendations for valve replacement surgery.(8) 
The utility of serial measurements of cardiac biomarkers (parti-
cularly N-terminal brain natriuretic peptide) to identify the optimal 
timing of aortic valve replacement in asymptomatic patients is still 
under investigation. More evidence is needed before the 
measurement of biomarkers as a risk stratifying tool is adopted in 
clinical practice.  
AS has been shown to be an infl ammatory process associated 
with cardiovascular risk factors with histopathological changes in 
the valve leafl ets similar to atherosclerosis. Given the clear 
relationship between atherosclerosis and AS it would seem that 
modifi cation of cardiovascular risk factors would seem an obvious 
method to retard the progression of aortic stenosis.  However, 
there is currently no good evidence that any medical therapy 
can retard the progression of AS.  
Although a number of small retrospective studies have suggested 
that statin therapy can possibly retard the progression of AS, 
two recent randomised controlled trials have failed to demon-
strate a reduction in the progression of aortic stenosis or hard 
clinical end-points.(16,17)  
In theory, ACE inhibition could play a role in preventing pro-
gression of AS as sclerotic aortic valves express Angiotensin II 
and ACE and pressure overload leads to progressive cardiac 
remodelling (hypertrophy and fi brosis). A single retrospective 
study failed to show a benefi cial effect of ACE-inhibitors on the 
progression of AS.(18) Historically, ACE inhibition was said to be 
contraindicated in the patients with AS.  The concern has been 
that ACE inhibitors would cause profound peripheral vasodilation 
and decreased coronary perfusion pressure that would result 
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in haemodynamic compromise, collapse and potentially death. 
A single study showed that patients with severe AS can tolerate 
ACE-inhibitors very well on initiation.(19) There is suffi cient theore-
tical evidence to support a randomised control trial to explore 
the role of ACE inhibition and AS.  It is our current practice not 
to commence ACE inhibitors in patients with severe asymptomatic 
AS but not to withdraw them if patients are tolerating them 
as many patients are often unknowingly established on such 
treatment without compromise.
No clinical trials have addressed whether interventions aimed 
at altering cardiovascular risk factors such as hypertension, 
diabetes or smoking have any effect on the progression of AS.    
AS with reduced ejection fraction
Reduced ejection fraction in patients with aortic stenosis can be 
caused either by the severe afterload or contractile dysfunction. 
It is important to differentiate between these two causes as a 
low ejection fraction caused by severe afterload usually responds 
to relief of the afterload and has a good prognosis because 
contractility is maintained and the ejection fraction improves post 
surgery. The mean transvalvular gradient is a good measure 
of afterload and, generally, the higher the gradient (mean gradient 
> 35mmHg), the greater the afterload and usually the better 
response to surgery.(20) Most of the above patients will be 
symptomatic. A minority may be asymptomatic and should 
undergo aortic valve replacement when the LVEF <=50%.  
Patients with AS and a reduced ejection fraction caused by 
contractile dysfunction generally have a poorer response to 
surgery because irreversible LV dysfunction rather than severe 
afterload is the cause of the reduced ejection fraction. These 
patients will typically have a small transvalvar gradient, with a 
small reduction in afterload and smaller improvement in ejection 
fraction post surgery. Low-fl ow, low-gradient AS is defi ned as 
a reduced ejection fraction (LVEF<=40%) and a low gradient 
(mean gradient < 30mmHg) with a valve area < 1.0cm2.  As the 
calculation of valve area in the Gorlin’s equation is fl ow depen-
dent, aortic valve area is highly dependent on cardiac output. 
As cardiac output can be reduced by any cause of contractile 
dysfunction, it is important to identify patients with truly severe 
AS (whose severe valve disease has led to severe LV dysfunction) 
or relative or pseudo-AS where the LV dysfunction is from 
another process, such as coronary artery disease, and the 
ventricle is unable to open a mildly but not severely stenotic 
aortic valve.  Dobutamine stress testing with calculation of 
the mean transvalvar gradient and aortic valve area by echo-
cardiography using the continuity equation has been used to help 
differentiate true AS from relative AS and, secondly, to further 
identify contractile reserve in patients with true AS.  Dobutamine 
will increase cardiac output in relative AS but the mean gradient 
will increase slightly or not at all with a large increase in calculated 
valve area.  This is in contrast to true AS where the cardiac output 
and mean gradient will increase with a minimal change in the 
calculated valve area (if there is contractile reserve).        
Patients with relative AS should not undergo surgery, and the 
patient’s prognosis is largely determined by the cause of the 
underlying LV dysfunction. Surgery is indicated if there is true 
AS and contractile reserve is demonstrated with dobutamine.  The 
surgical risk is very high in patients without contractile reserve 
and surgery should not be recommended.  Although division into 
these categories may help guide therapeutic decisions, we still 
lack large follow-up studies evaluating their effect on long-term 
prognosis. In the largest study published to date, Monin et al. 
showed that when contractile reserve was present, 6 year 
survival after aortic valve replacement was 75%.(22) When 
contractile reserve was absent, prognosis was much worse, 
although even some patients without contractile reserve 
improved post surgery.  Methods to identify this latter group of 
patients whom may benefi t still needs to be identifi ed.
AS in elderly patients 
Symptom onset is often diffi cult to determine in the elderly. 
Fatigue rather than dyspnoea can be the sign of limited effort 
tolerance. History should also address patients’ wishes and 
examination should focus on co-morbidities. Coronary angio-
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Adapted from Bermejo et al.(21)
Relative AS Area > 0.3cm2 and/or area > 1.2cm2
True AS with contractile reserve   > = 20% increase in stroke volume and 
area < 1.2cm2




















graphy is indicated before surgery and is an important compo-
nent of decision-making as coronary disease will infl uence 
operative risk and prognosis.  The benefi t of surgery on late 
outcome should be interpreted in the light of life expectancy. 
There have been many studies to date that have shown that 
there is almost no age limit for aortic valve surgery in patients 
with aortic stenosis in the absence of comorbid disease.(23) 
Operative mortality of aortic valve replacement is approximately 
10% in patients over 80 years of age. The decision to operate 
relies on a team approach (cardiac surgeon, anaesthetist, cardio-
logist, geriatrician) with an accurate estimation of the risk/benefi t 
ratio, comorbidity, operative mortality and life expectancy. 
   
AS and regurgitation
Many patients will have a combination of AS and regurgitation. 
These patients should be evaluated and managed with standard 
diagnostic approaches described above.  It must be emphasised 
that symptoms may develop when AS and regurgitation is quantifi ed 
as “moderate”.(24) Aortic valve replacement is clearly indicated 
in patients who are symptomatic, LV systolic function is <=50% 
or at the time of other cardiac surgery.
AS and hypertension
AS and hypertension frequently co-exist in the same patient. 
Hypertension can mask the physical fi ndings of AS especially in 
the elderly patient.  Hypertension may result in the carotid pulse 
having a rapid upstroke and normal amplitude as well as a 
diminished murmur because of increased vessel stiffness and 
peripheral aortic impedance.  The combined effect of aortic valvar 
obstruction (AS) and increased systemic vascular resistance 
(hypertension) on the double-loaded left ventricle is still not 
fully understood.(25) Hypertension may reduce aortic transvalvar 
fl ow rates and consequently transvalvar gradient. Therefore, 
calculation of aortic valve area by either the continuity equation 
during echocardiography or by cardiac catheterisation using 
Gorlins’ equation may be more accurate than transvalvar 
gradients/velocities. Thus evaluation of AS severity should 
preferably be performed when patients are normotensive. The 
best drug for lowering blood pressure in the presence of AS 
has not been established. Anti-hypertensives should be started 
at low doses with careful dose escalation. We would begin with 
a diuretic with careful introduction of an ACE-inhibitor to 
control blood pressure (in patients who do not have severe AS). 
AS and coronary artery disease 
Signifi cant coronary disease occurs in about 30% of pre-
operative cardiac catheterisation.(24) Patients with severe aortic 
stenosis should undergo coronary artery bypass grafting of 
signifi cant lesions at the time of surgery.  Patients due to undergo 
coronary artery bypass grafting with moderate/severe AS 
should undergo valve surgery.  A challenging group are patients 
with a chest pain and both coronary artery disease and 
moderate AS.  Studies testing for inducible ischaemia have a 
lower diagnostic accuracy in patients with AS.
AS and noncardiac surgery
Patients with severe asymptomatic AS who require emergent 
non-cardiac surgery should undergo non-cardiac surgery without 
aortic valve evaluation. Patients with symptomatic AS should 
generally undergo valve replacement before elective surgery. 
There are small case series showing that surgery can be performed 
at an acceptable risk in patients with asymptomatic severe AS.(26)
PERCUTANEOUS AORTIC VALVE REPLACEMENT    
Percutaneous implantation of an aortic valve seems to offer a 
durable improvement in valve function at a lower risk than aortic 
valve replacement.  Initial experience has demonstrated the 
feasibility of this approach in patients with severe co-morbidities 
and contra-indications to surgery.  Growing experience and ongoing 
trials in patients at high operative risk will allow more accurate 
evaluation of this procedure. 
CONCLUSION                                                                 
We have attempted to highlight some of the pitfalls in the diagnosis 
and management of AS.  In many instances, the estimation of severity 
of aortic stenosis and the timing of valve replacement surgery is 
easy.  In older patients and those with concomitant coronary, 
pulmonary or other disease it may be extraordinarily diffi cult.  In 
truly asymptomatic patients the matter of severity of AS does not 
usually need to be pursued.  In any symptomatic patient, once the 
possibility of AS has been entertained, investigation needs to be 
continued until the severity of the AS and its contribution to the 
symptoms has been clearly established.
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